{
    "clinical_study": {
        "@rank": "146486", 
        "arm_group": {
            "arm_group_label": "Thirty milligrams of lansoprazole", 
            "description": "Thirty milligrams of lansoprazole is mixed in physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by drip infusion or dissolved in 20 mL of physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by direct slow intravenous injection."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this survey is to evaluate the safety (i.e., frequency of adverse events) and\n      efficacy (i.e., hemostatic effect, rate of rebleeding after confirmation of hemostasis) of\n      administration of lansoprazole intravenous 30 mg (Takepron Intravenous 30 mg) to a large\n      number of patients in daily medical practice."
        }, 
        "brief_title": "Lansoprazole Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Rebleeding Rate]", 
        "completion_date": {
            "#text": "March 2010", 
            "@type": "Actual"
        }, 
        "condition": "Gastric Ulcer, Duodenal Ulcer, Acute Stress Gastritis, and Acute Gastric Mucosal Lesions", 
        "condition_browse": {
            "mesh_term": [
                "Duodenal Ulcer", 
                "Gastritis", 
                "Stomach Ulcer", 
                "Ulcer"
            ]
        }, 
        "detailed_description": {
            "textblock": "This survey was designed to evaluate the safety (i.e., frequency of adverse events) and\n      efficacy (i.e., hemostatic effect, rate of rebleeding after confirmation of hemostasis) of\n      administration of lansoprazole intravenous 30 mg (Takepron Intravenous 30 mg) to a large\n      number of patients in daily medical practice.\n\n      For adults, 30 mg of lansoprazole is typically mixed in physiological saline (JP) or 5%\n      glucose solution for injection (JP) and administered twice daily by drip infusion or\n      dissolved in 20 mL of physiological saline (JP) or 5% glucose solution for injection (JP)\n      and administered twice daily by direct slow intravenous injection."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with the following diseases for whom oral administration is not feasible:\n\n        Gastric ulcer, duodenal ulcer, acute stress gastritis, and acute gastric mucosal lesion\n        (all of which should be accompanied by bleeding).\n\n        Exclusion Criteria:\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Gastric ulcer, duodenal ulcer, acute stress gastritis, and acute gastric mucosal lesions"
            }
        }, 
        "enrollment": {
            "#text": "1120", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02151786", 
            "org_study_id": "254-011"
        }, 
        "intervention": {
            "arm_group_label": "Thirty milligrams of lansoprazole", 
            "description": "Lansoprazole intravenous 30 mg", 
            "intervention_name": "Lansoprazole", 
            "intervention_type": "Drug", 
            "other_name": "Takepron Intravenous 30 mg"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Hemostatics", 
                "Lansoprazole"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pharmacological therapy", 
        "lastchanged_date": "May 28, 2014", 
        "number_of_groups": "1", 
        "official_title": "Takepron Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Rebleeding Rate]", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The frequencies of all adverse events observed during the observation period will be tabulated by type and seriousness. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with administration of lansoprazole whether or not it was considered related to treatment. Among these, events that are considered as having a causal relationship with lansoprazole are defined as adverse drug reactions.", 
            "measure": "Frequency of adverse events (adverse drug reactions)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 9 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02151786"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "In patients for whom hemostasis is confirmed by endoscopy, the frequencies of hemostatic effects of lansoprazole intravenous 30 mg are tabulated by the degree of improvement (i.e., \"markedly improved,\" \"moderately improved,\" \"slightly improved,\" and \"poor\").", 
                "measure": "Hemostatic effect", 
                "safety_issue": "No", 
                "time_frame": "Up to 9 weeks from baseline"
            }, 
            {
                "description": "In patients for whom hemostasis is confirmed by endoscopy performed after the start of treatment with lansoprazole intravenous 30 mg, the rebleeding rates during the period starting from baseline until the completion of treatment with lansoprazole intravenous 30 mg are tabulated.", 
                "measure": "Rebleeding rate during treatment with lansoprazole 30 mg Injection", 
                "safety_issue": "No", 
                "time_frame": "Up to 9 weeks from baseline"
            }, 
            {
                "description": "In patients for whom hemostasis is confirmed by endoscopy, the rebleeding rates at 8 weeks after the completion of treatment with lansoprazole intravenous 30 mg are tabulated.", 
                "measure": "Rebleeding rate after the completion of treatment with lansoprazole intravenous 30 mg", 
                "safety_issue": "No", 
                "time_frame": "Up to 9 weeks from baseline"
            }
        ], 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2007", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}